Molecule Details
InChIKeyIMSSROKUHAOUJS-MJCUULBUSA-N
Canonical SMILESC#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OC)ccc4[C@H]3CC[C@@]21C
Clinical Status Data-mined Candidate
Targets (Human+Pathogen)2
Pfam Stratification Cross-Family
Avg pChEMBL7.77
SourceChEMBL
2D Structure
2D structure
Activity Profile
DrugBank Annotations
DrugBank ID DB01357
Drug NameMestranol
CAS Number72-33-3
Groups approved withdrawn
ATC Codes nan
DescriptionThe 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives.

Categories: Adrenal Cortex Hormones Contraceptive Agents, Female Contraceptive Agents, Hormonal Contraceptives, Oral Contraceptives, Oral, Hormonal Cytochrome P-450 CYP2C8 Substrates Cytochrome P-450 CYP2C9 Substrates Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Substrates Estradiol Congeners Estrogen Contraceptives Estrogenic Steroids, Alkylated Estrogens Ethinyl Estradiol Fused-Ring Compounds Gonadal Hormones Gonadal Steroid Hormones Hormonal Contraceptives for Systemic Use Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Hyperglycemia-Associated Agents Norpregnanes Norpregnatrienes Norsteroids Reproductive Control Agents Steroids Thyroxine-binding globulin inducers
Cross-references: ChEBI: 6784 CHEMBL1201151 ChemSpider: 6054 Drugs Product Database (DPD): 7429 C07618 D00575 PharmGKB: PA450388 PubChem:6291 PubChem:46507679 RxCUI: 6782 Therapeutic Targets Database: DAP001014 Wikipedia: Mestranol ZINC: ZINC000003815424
Target Activities (2)
Target Gene Organism Category Pfam pChEMBL Type Source
P03372 ESR1 Homo sapiens Human PF12743 PF00104 PF02159 PF00105 8.0 IC50 ChEMBL
P31645 SLC6A4 Homo sapiens Human PF03491 PF00209 7.5 IC50 ChEMBL
DrugBank Target Actions (4)
Target Gene Target Name Action Type
P08684 CYP3A4 Cytochrome P450 3A4 substrate enzymes
P10632 CYP2C8 Cytochrome P450 2C8 substrate enzymes
P11712 CYP2C9 Cytochrome P450 2C9 substrate enzymes
P03372 ESR1 Estrogen receptor agonist targets